Basilea Pharmaceutica AG (BSLN.SW)
| Previous close | 39.05 |
| Open | 39.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 39.00 - 40.00 |
| 52-week range | 32.00 - 49.00 |
| Volume | |
| Avg. volume | 24,569 |
| Market cap | 479.243M |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | 46.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Apr 2013 |
| 1y target est | N/A |
- GlobeNewswire
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea’s oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma, the most common type of primary brain can
- GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s Ch
- GlobeNewswire
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera®) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024
